ARASENS Trial: Should darolutamide now be added to androgen-deprivation therapy and docetaxel in patients with metastatic, hormone-sensitive prostate cancer?

被引：1
|
作者：
Kumar, Naveen [1 ]
机构：
[1] Medanta Hosp, Dept Urol, Patna, Bihar, India
来源：
INDIAN JOURNAL OF UROLOGY | 2022年 / 38卷 / 03期
关键词：
D O I：
10.4103/iju.iju_81_22
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：238 / 239
页数：2
相关论文
共 50 条
  • [21] Efficacy and safety of darolutamide in combination with androgen-deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial
    Tombal, B.
    Hussain, M.
    Saad, F.
    Fizazi, K.
    Shore, N.
    Kopyltsov, E.
    Boegemann, M.
    Mendez-Vidal, M. J.
    Littleton, N.
    Srinivasan, S.
    Verholen, F.
    Smith, M. R.
    EUROPEAN UROLOGY, 2024, 85 : S1585 - S1585
  • [22] COST-EFFECTIVENESS OF ADDING DAROLUTAMIDE TO DOCETAXEL AND ANDROGEN DEPRIVATION THERAPY IN THE TREATMENT OF METASTATIC HORMONE-SENSITIVE PROSTRATE CANCER
    Nwogu, I. B.
    Nedzesky, J.
    Carlson, J. J.
    VALUE IN HEALTH, 2023, 26 (06) : S106 - S106
  • [23] Darolutamide in Japanese patients with metastatic hormone-sensitive prostate cancer: Phase 3 ARASENS subgroup analysis
    Uemura, Motohide
    Kikukawa, Hiroaki
    Hashimoto, Yasuhiro
    Uemura, Hiroji
    Mizokami, Atsushi
    Kato, Masashi
    Matsushima, Hisashi
    Kosaka, Takeo
    Nakamura, Motonobu
    Fukasawa, Satoshi
    Smith, Matthew R.
    Tombal, Bertrand
    Hussain, Maha
    Saad, Fred
    Fizazi, Karim
    Sternberg, Cora N.
    Crawford, E. David
    Kakiuchi, Haruka
    Akiyama, Masanao
    Li, Rui
    Kuss, Iris
    Joensuu, Heikki
    Suzuki, Hiroyoshi
    CANCER MEDICINE, 2024, 13 (21):
  • [24] Addition of docetaxel or abiraterone to androgen deprivation therapy in metastatic hormone-sensitive prostate cancer in Indian population
    Gupta, Alok
    Hussain, Shaik Maheboob
    Sonthwal, Neha
    Chaturvedi, Harit
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2021, 17 (02) : 389 - 392
  • [25] Efficacy and Safety of Androgen-Deprivation Therapy Combined with Docetaxel Plus Prednisone in High-Burden Metastatic Hormone-Sensitive Prostate Cancer
    Hu, Linjun
    Zhao, Qinxin
    Bai, Hongsong
    Xie, Chengming
    Shan, Xingli
    Lu, Dehu
    Chen, Yonghai
    Han, Dongdong
    Xiao, Zejun
    Tian, Jun
    Wang, Dong
    Bi, Xingang
    Xing, Nianzeng
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 4369 - 4377
  • [26] Use of docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in Korean patients: A retrospective study
    Kwon, Whi-An
    Joung, Jae Young
    Lee, Jung Eun
    Choi, Se Young
    Kim, Sung Han
    Seo, Ho Kyung
    Lee, Kang Hyun
    Kim, Choung-Soo
    INVESTIGATIVE AND CLINICAL UROLOGY, 2019, 60 (03) : 195 - 201
  • [27] EFFICACY AND SAFETY OF DAROLUTAMIDE IN COMBINATION WITH ANDROGEN-DEPRIVATION THERAPY AND DOCETAXEL IN THE NORTH AMERICAN POPULATION FROM ARASENS
    Shore, Neal D.
    Tombal, Bertrand
    Hussain, Maha
    Saad, Fred
    Fizazi, Karim
    Sternberg, Cora N.
    Crawford, E. David
    Nordquist, Luke
    Tutrone, Ronald
    Belkoff, Laurence
    Kapur, Shivani
    Jhaveri, Jay
    Srinivasan, Shankar
    Joensuu, Heikki
    Smith, Matthew R.
    JOURNAL OF UROLOGY, 2023, 209 : E380 - E380
  • [28] Cost-effectiveness analysis of additional docetaxel for metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy from a Chinese perspective
    Zheng, H. R.
    Wen, F.
    Wu, Y. F.
    Wheeler, J. R. C.
    Li, Q.
    EUROPEAN JOURNAL OF CANCER CARE, 2017, 26 (06)
  • [29] Cost-effectiveness of rezvilutamide versus bicalutamide and androgen-deprivation therapy in patients with highvolume, metastatic, hormone-sensitive prostate cancer
    Wu, Huina
    Sun, Lei
    Feng, Rui
    Zhang, Huiyue
    Tang, Ke
    Wang, Shuo
    Nie, Jing
    FRONTIERS IN PHARMACOLOGY, 2024, 14
  • [30] Docetaxel chemotherapy plus androgen-deprivation therapy in high-volume disease metastatic hormone-sensitive prostate cancer in Chinese patients: an efficacy and safety analysis
    Zhuifeng Guo
    Xuwei Lu
    Fan Yang
    Liang Qin
    Ning Yang
    Jiawen Wu
    Hang Wang
    European Journal of Medical Research, 27
12345